Celldex Therapeutics Inc

자세한 내용은 Celldex Therapeutics Inc 회사

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

회사 정보

종목 코드 CLDX

회사 이름Celldex Therapeutics Inc

상장일May 15, 1986

CEOMr. Anthony S. Marucci

직원 수186

유형Ordinary Share

회계 연도 종료May 15

주소53 Frontage Road

도시HAMPTON

증권 거래소NASDAQ Capital Market Consolidated

국가United States of America

우편 번호08827

전화19084547120

웹사이트https://celldex.com/

종목 코드 CLDX

상장일May 15, 1986

CEOMr. Anthony S. Marucci

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Anthony S. Marucci

President, Chief Executive Officer, Director

40.64K

+1.48%

Mr. Freddy A. Jimenez, Esq., J.D.

Senior Vice President, General Counsel

34.14K

+38.79%

Dr. Diane C. Young, M.D.

Senior Vice President, Chief Medical Officer

17.11K

-63.67%

Dr. Margo Heath-Chiozzi, M.D.

Senior Vice President - Regulatory Affairs

13.74K

+2.70%

Ms. Elizabeth Crowley

Senior Vice President, Chief Product Development Officer

9.07K

--

Dr. Tibor Keler, Ph.D.

Executive Vice President, Chief Scientific Officer

7.36K

--

Mr. Herbert J. (Herb) Conrad

Independent Director

2.56K

--

Mr. James J. (Jim) Marino

Independent Director

2.20K

--

Mr. Keith L. Brownlie, CPA

Independent Director

666.00

--

Ms. Denice M. Torres, J.D.

Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Anthony S. Marucci

President, Chief Executive Officer, Director

40.64K

+1.48%

Mr. Freddy A. Jimenez, Esq., J.D.

Senior Vice President, General Counsel

34.14K

+38.79%

Dr. Diane C. Young, M.D.

Senior Vice President, Chief Medical Officer

17.11K

-63.67%

Dr. Margo Heath-Chiozzi, M.D.

Senior Vice President - Regulatory Affairs

13.74K

+2.70%

Ms. Elizabeth Crowley

Senior Vice President, Chief Product Development Officer

9.07K

--

Dr. Tibor Keler, Ph.D.

Executive Vice President, Chief Scientific Officer

7.36K

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

Wellington Management Company, LLP

12.58%

Kynam Capital Management LP

9.79%

BlackRock Institutional Trust Company, N.A.

6.97%

Fidelity Management & Research Company LLC

5.85%

The Vanguard Group, Inc.

5.85%

Other

58.95%

주주

비율

Wellington Management Company, LLP

12.58%

Kynam Capital Management LP

9.79%

BlackRock Institutional Trust Company, N.A.

6.97%

Fidelity Management & Research Company LLC

5.85%

The Vanguard Group, Inc.

5.85%

Other

58.95%

주주 유형

주주

비율

Investment Advisor

45.68%

Hedge Fund

31.15%

Investment Advisor/Hedge Fund

29.65%

Research Firm

3.45%

Venture Capital

2.56%

Bank and Trust

0.33%

Pension Fund

0.31%

Individual Investor

0.27%

Insurance Company

0.04%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

419

75.39M

113.55%

-14.43M

2025Q1

437

75.31M

113.46%

-13.68M

2024Q4

437

75.05M

113.05%

-8.14M

2024Q3

429

73.28M

110.59%

-7.16M

2024Q2

432

71.48M

107.86%

-10.62M

2024Q1

419

71.32M

108.50%

+952.72K

2023Q4

406

62.72M

112.33%

-412.93K

2023Q3

403

52.10M

110.18%

-8.63M

2023Q2

410

51.84M

109.57%

-7.47M

2023Q1

419

51.38M

108.89%

-6.42M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Wellington Management Company, LLP

8.35M

12.58%

-621.68K

-6.93%

Mar 31, 2025

Kynam Capital Management LP

6.50M

9.79%

+1.44M

+28.35%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.62M

6.97%

-29.87K

-0.64%

Mar 31, 2025

Fidelity Management & Research Company LLC

3.89M

5.85%

+441.18K

+12.80%

Mar 31, 2025

The Vanguard Group, Inc.

3.89M

5.85%

+16.44K

+0.42%

Mar 31, 2025

Eventide Asset Management, LLC

3.75M

5.66%

+1.53K

+0.04%

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.35M

5.05%

-144.43K

-4.13%

Mar 31, 2025

Commodore Capital LP

3.35M

5.05%

+150.00K

+4.69%

Apr 03, 2025

Bellevue Asset Management AG

3.07M

4.63%

--

Mar 31, 2025

State Street Global Advisors (US)

2.81M

4.23%

-428.60K

-13.25%

Mar 31, 2025

21.860USD

Celldex Therapeutics Inc

21.860

개요

회사

금융